PsychonautWiki Archive

Methylphenidate: Difference between revisions

← Older edit
>MeyveliPasta
add erectile dysfunction effect
>Larnaca
m Undo partial reversion
 
(25 intermediate revisions by 10 users not shown)
Line 1: Line 1:
{{SummarySheet}}
{{SummarySheet}}
{{SubstanceBox/Methylphenidate}}
{{SubstanceBox/Methylphenidate}}
'''Methylphenidate''' (also known as '''MPH''', '''MPD''', and the trade names '''Ritalin''', '''Concerta''', and '''Methylin''', among others) is a classical [[psychoactive class::stimulant]] substance of the [[chemical class::phenidate]] class. It is the parent compound of the [[substituted phenidates]], a family of stimulants that includes [[ethylphenidate]], [[isopropylphenidate]], and others. The mechanism of action involves increasing concentrations of the [[neurotransmitters]] [[dopamine]] and [[norepinephrine]].
'''Methylphenidate''' (also known as '''MPH''', '''MPD''', and the trade names '''Ritalin''', '''Concerta''', and '''Methylin''', among others) is a classical potent [[psychoactive class::stimulant]] substance of the [[chemical class::phenidate]] class. It is the parent compound of the [[substituted phenidates]], a family of stimulants that includes [[ethylphenidate]], [[isopropylphenidate]], and others. The mechanism of action involves increasing concentrations of the [[neurotransmitters]] [[dopamine]] and [[norepinephrine]].


It was first synthesized in 1944 and was approved for medical use in the United States in 1955. It was originally sold by Swiss company CIBA (now Novartis).<ref>{{cite journal | vauthors=((Lange, K. W.)), ((Reichl, S.)), ((Lange, K. M.)), ((Tucha, L.)), ((Tucha, O.)) | journal=ADHD Attention Deficit and Hyperactivity Disorders | title=The history of attention deficit hyperactivity disorder | volume=2 | issue=4 | pages=241–255 | date= December 2010 | url=http://link.springer.com/10.1007/s12402-010-0045-8 | issn=1866-6116 | doi=10.1007/s12402-010-0045-8}}</ref> It is approved for treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy. It is often used by students with or without ADHD as a cognitive enhancer and study aid.
It was first synthesized in 1944 and was approved for medical use in the United States in 1955. It was originally sold by Swiss company CIBA (now Novartis).<ref>{{cite journal | vauthors=((Lange, K. W.)), ((Reichl, S.)), ((Lange, K. M.)), ((Tucha, L.)), ((Tucha, O.)) | journal=ADHD Attention Deficit and Hyperactivity Disorders | title=The history of attention deficit hyperactivity disorder | volume=2 | issue=4 | pages=241–255 | date= December 2010 | url=http://link.springer.com/10.1007/s12402-010-0045-8 | issn=1866-6116 | doi=10.1007/s12402-010-0045-8}}</ref> It is approved for treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy. It is often used by students with or without ADHD as a cognitive enhancer and study aid.


[[Subjective effects]] include [[stimulation]], [[focus enhancement]], [[motivation enhancement]], [[increased libido]], [[appetite suppression]], and [[euphoria]]. It is usually taken orally, but can also be [[Routes of administration|insufflated or administered rectally]]. The effects are comparable to those of amphetamine; however, it is reported to produce less euphoria and generally have less recreational value. Some users also report it produces a stronger comedown relative to amphetamine.
[[Subjective effects]] include [[stimulation]], [[focus enhancement]], [[motivation enhancement]], [[increased libido]], [[appetite suppression]], and [[euphoria]]. It is usually taken orally, but can also be [[Routes of administration|insufflated or administered rectally]]. The effects are comparable to those of amphetamine; however, it is reported to produce less euphoria and generally have less recreational value. Some users also report it produces a stronger comedown relative to amphetamine especially with high doses.


It has moderate abuse potential. Chronic use (i.e. high dose, repeat administration) is associated with [[compulsive redosing]], escalating tolerance, and psychological dependence. It is highly advised to use [[harm reduction]] practices if using this substance.  
It has moderate abuse potential. Chronic use (i.e. high dose, repeat administration) is associated with [[compulsive redosing]], escalating tolerance, and psychological dependence. It is highly advised to use [[harm reduction]] practices if using this substance.  


==History and culture==
==History and culture==
{{historyStub}}
Methylphenidate was first licensed by the U.S. Food and Drug Administration (FDA) in 1955 for treating what was then known as "hyperactivity."{{citation needed}} Although it was prescribed to patients as early as 1960, it only became heavily prescribed in the 1990s when the diagnosis of ADHD itself became more widely accepted.<ref>{{cite book | vauthors=((Diller, L. H.)) | date= 1999 | title=Running on ritalin: a physician reflects on children, society, and performance in a pill | publisher=Bantam Books | isbn=9780553379068}}</ref><ref>{{cite journal | vauthors=((Lange, K. W.)), ((Reichl, S.)), ((Lange, K. M.)), ((Tucha, L.)), ((Tucha, O.)) | journal=Attention Deficit and Hyperactivity Disorders | title=The history of attention deficit hyperactivity disorder | volume=2 | issue=4 | pages=241–255 | date= 2010 | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000907/ | issn=1866-6116 | doi=10.1007/s12402-010-0045-8}}</ref>


It was estimated that the number of doses of methylphenidate used globally in 2013 increased by 66% compared to 2012.<ref>{{cite journal | journal=The Pharmaceutical Journal | title=Narcotics monitoring board reports 66% increase in global consumption of methylphenidate | date= 2015 | url=http://www.pharmaceutical-journal.com/news-and-analysis/news-in-brief/narcotics-monitoring-board-reports-66-increase-in-global-consumption-of-methylphenidate/20068042.article | issn=2053-6186 | doi=10.1211/PJ.2015.20068042}}</ref> In 2019, it was the 51st most commonly prescribed medication in the United States, with more than 14 million prescriptions.<ref>{{cite web |title=The Top 300 of 2019 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=ClinCalc |access-date=16 October 2021 }}</ref><ref>{{cite web | title=Methylphenidate - Drug Usage Statistics | website=ClinCalc | url=https://clincalc.com/DrugStats/Drugs/Methylphenidate | access-date=16 October 2021}}</ref> It is available as a generic medication.
The compound was first synthesized in 1944 by chemist Leandro Panizzon and marketed as “Ritalin” by Swiss company CIBA (now Novartis) in 1954. The name “Ritalin” derives from the first name of Panizzon’s wife, i.e. Marguerite, nicknamed Rita,<ref>https://pmc.ncbi.nlm.nih.gov/articles/PMC3000907/#Sec8</ref> who used Ritalin to compensate for low blood pressure.<ref>Richard L. Myers https://books.google.com/books?id=a4DuGVwyN6cC&q=named+ritalin+after+his+wife&pg=PA178 ABC-CLIO. p. 178. ISBN 978-0-313-33758-1.</ref>
 
Methylphenidate was not reported to be a stimulant until 1954.<ref>Heal DJ, Pierce DM (2006). "Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system". ''CNS Drugs''. '''20''' (9): 713–738. doi:[https://link.springer.com/article/10.2165/00023210-200620090-00002 10.2165/00023210-200620090-00002]. [https://pubmed.ncbi.nlm.nih.gov/16953648/ PMID 16953648.] [https://www.semanticscholar.org/paper/Methylphenidate-and-its-Isomers-Heal-Pierce/b19872ac87ae24e3cd161a1719d192b9fccffa1b S2CID 39535277.]</ref> The drug was introduced for medical use in the United States in 1957.<ref>Wood S, Sage JR, Shuman T, Anagnostaras SG (2014). "Psychostimulants and cognition: A continuum of behavioral and cognitive activation". ''Pharmacol Rev''. '''66''' (1): 193–221. https://pmc.ncbi.nlm.nih.gov/articles/PMC3880463/</ref> Although it was first used to allay [[Barbiturates|barbiturate]]-induced coma, narcolepsy, and depression.<ref>Myers RL (August 2007). [https://archive.org/details/100mostimportant0000myer ''The 100 Most Important Chemical Compounds: A reference guide''.] ABC-CLIO. p. 178. [[ISBN (identifier)|ISBN]] [[Special:BookSources/978-0-313-33758-1|<bdi>978-0-313-33758-1</bdi>]].</ref> It was later used to treat memory deficits in the elderly.<ref>Stolerman I (2010). ''Encyclopedia of Psychopharmacology''. Berlin, DE / London, UK: Springer. p. 763. ISBN [[Special:BookSources/978-3-540-68698-9|<bdi>978-3-540-68698-9</bdi>]].</ref> Production and prescription only rose significantly in the 1990s, especially in the United States, as the ADHD diagnosis came to be better understood and more generally accepted within the medical and mental health communities.<ref>Woodworth T (16 May 2000). [https://web.archive.org/web/20071012061712/http://www.dea.gov/pubs/cngrtest/ct051600.htm DEA Congressional Testimony (Report)]. U.S. Drug Enforcement Administration. Archived from [https://www.dea.gov/pubs/cngrtest/ct051600.htm the original] on 12 October 2007. Retrieved 2 November 2007.</ref>
 
In 2000, Alza Corporation received US FDA approval to market Concerta, an extended-release form of methylphenidate.<ref>[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd "Concerta- methylphenidate hydrochloride tablet, extended release"]. ''DailyMed''. 1 July 2021.</ref><ref>[https://web.archive.org/web/20101216171133/http://centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=637 "Newly Approved Drug Therapies (637) Concerta, Alza".] ''CenterWatch''. Archived from [https://www.centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=637 the original] on 16 December 2010. Retrieved 30 April 2011.</ref>
 
It was estimated that the number of doses of methylphenidate used globally in 2013 increased by 66% compared to 2012.<ref>{{cite journal | journal=The Pharmaceutical Journal | title=Narcotics monitoring board reports 66% increase in global consumption of methylphenidate | date= 2015 | url=http://www.pharmaceutical-journal.com/news-and-analysis/news-in-brief/narcotics-monitoring-board-reports-66-increase-in-global-consumption-of-methylphenidate/20068042.article | issn=2053-6186 | doi=10.1211/PJ.2015.20068042}}</ref> In 2022, it was the 32nd most commonly prescribed medication in the United States, with more than 17 million prescriptions.<ref>[https://clincalc.com/DrugStats/Drugs/Methylphenidate "Methylphenidate Drug Usage Statistics, United States, 2013 - 2022"]. ''ClinCalc''. Retrieved 30 August 2024.</ref> It is available as a generic medication.<ref>[https://www.drugs.com/monograph/methylphenidate.html "Methylphenidate Hydrochloride Monograph for Professionals".] ''Drugs.com''. AHFS. Archived from [https://web.archive.org/web/20181003194029/https://www.drugs.com/monograph/methylphenidate-hydrochloride.html the original] on 19 December 2018. Retrieved 19 December 2018.</ref>


==Chemistry==
==Chemistry==
Methylphenidate is a synthetic molecule of the [[substituted phenethylamine]] and [[substituted phenidate]] classes. It contains a phenethylamine core featuring a phenyl ring bound to an amino (-NH<sub>2</sub>) group through an ethyl chain.  
Methylphenidate is a synthetic molecule of the [[substituted phenethylamine]] and [[substituted phenidate]] classes. It contains a phenethylamine core featuring a phenyl ring bound to an amino (-NH<sub>2</sub>) group through an ethyl chain.  


It is structurally similar to [[amphetamine]], featuring a substitution at R<sub>α</sub> which is incorporated into a [[piperidine]] ring ending at the terminal amine of the phenethylamine chain. Additionally, it contains a methyl acetate bound to R<sub>β</sub> of its structure.  
It is structurally similar to [[amphetamine]], featuring a substitution at R<sub>α</sub> which is incorporated into a [[piperidine]] ring ending at the terminal amine of the phenethylamine chain. Additionally, it contains a methyl carboxylate bound to R<sub>β</sub> of its structure.  
 
The solubility of methylphenidate hcl is 29.3 mg/ml for ethanol and 18.6 mg/ml for water.<ref>https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/226/863/m2892dat.pdf</ref>


===Dexmethylphenidate===
===Dexmethylphenidate===
Line 48: Line 50:
|{{effects/physical|
|{{effects/physical|


*'''[[Effect::Stimulation]]''' - Methylphenidate is usually reported to be energetic and stimulating in a fashion that is distinct but much weaker than that of [[amphetamine]] or [[methamphetamine]] and stronger than that of [[modafinil]] and [[caffeine]]. At lower to moderate doses, it encourages general productivity but at higher dosages it can encourage physical activities such as dancing, socializing, running, or cleaning. The particular style of stimulation which methylphenidate presents can be described as forced. This means that at higher dosages, it becomes difficult or impossible to keep still as jaw clenching, involuntarily bodily shakes and vibrations become present, resulting in extreme shaking of the entire body, unsteadiness of the hands, and a general lack of motor control.  
*'''[[Effect::Stimulation]]''' Methylphenidate is usually reported to be highly energetic and distinctively stimulating, similar to [[amphetamine]] or [[cocaine]] and stronger than [[modafinil]] and [[caffeine]]. At lower to moderate doses, it encourages general productivity but at higher dosages it can encourage physical activities such as dancing, socializing, running, or cleaning. The particular style of stimulation which methylphenidate presents can be described as forced. This means that at higher dosages, it becomes difficult or impossible to keep still as jaw clenching, involuntarily bodily shakes and vibrations become present, resulting in extreme shaking of the entire body, unsteadiness of the hands, and a general lack of motor control.
*'''[[Effect::Spontaneous bodily sensations]]'''
*'''[[Effect::Increased heart rate]]'''<ref name="Montastruc">{{cite journal | vauthors=((Montastruc, F.)), ((Montastruc, G.)), ((Montastruc, J.-L.)), ((Revet, A.)) | journal=BMJ | title=Cardiovascular safety of methylphenidate should also be considered in adults | pages=i3418 | date=22 June 2016 | url=https://www.bmj.com/lookup/doi/10.1136/bmj.i3418 | issn=1756-1833 | doi=10.1136/bmj.i3418}}</ref><ref name="Leonard">{{cite journal | vauthors=((Leonard, B. E.)), ((McCartan, D.)), ((White, J.)), ((King, D. J.)) | journal=Human Psychopharmacology: Clinical and Experimental | title=Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects | volume=19 | issue=3 | pages=151–180 | date= April 2004 | url=https://onlinelibrary.wiley.com/doi/10.1002/hup.579 | issn=0885-6222 | doi=10.1002/hup.579}}</ref>
*'''[[Effect::Increased heart rate]]'''<ref name="Montastruc">{{cite journal | vauthors=((Montastruc, F.)), ((Montastruc, G.)), ((Montastruc, J.-L.)), ((Revet, A.)) | journal=BMJ | title=Cardiovascular safety of methylphenidate should also be considered in adults | pages=i3418 | date=22 June 2016 | url=https://www.bmj.com/lookup/doi/10.1136/bmj.i3418 | issn=1756-1833 | doi=10.1136/bmj.i3418}}</ref><ref name="Leonard">{{cite journal | vauthors=((Leonard, B. E.)), ((McCartan, D.)), ((White, J.)), ((King, D. J.)) | journal=Human Psychopharmacology: Clinical and Experimental | title=Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects | volume=19 | issue=3 | pages=151–180 | date= April 2004 | url=https://onlinelibrary.wiley.com/doi/10.1002/hup.579 | issn=0885-6222 | doi=10.1002/hup.579}}</ref>
*'''[[Effect::Abnormal heartbeat]]'''<ref name="Montastruc" /><ref name="Leonard" />
*'''[[Effect::Abnormal heartbeat]]'''<ref name="Montastruc" /><ref name="Leonard" />
Line 57: Line 60:
*'''[[Effect::Increased perspiration]]'''
*'''[[Effect::Increased perspiration]]'''
*'''[[Effect::Nausea]]'''<ref name="Leonard" /> - May occur at higher doses, although tends to fade after a short period.
*'''[[Effect::Nausea]]'''<ref name="Leonard" /> - May occur at higher doses, although tends to fade after a short period.
*'''[[Effect::Dizziness]]'''<ref name="Leonard" /> - May occur at higher doses, although tends to fade after a short period.
*'''[[Effect::Dizziness]]'''<ref name="Leonard" />  
*'''[[Effect::Teeth grinding]]''' - Teeth grinding is present, but typically at higher doses and not to the same extent as other stimulants like [[amphetamine]], or more severely, [[MDMA]].
*'''[[Effect::Teeth grinding]]''' - Teeth grinding may be present at higher doses. However, it is less intense than that of [[MDMA]].
*'''[[Effect::Vasoconstriction]]'''
*'''[[Effect::Vasoconstriction]]'''
*'''[[Effect::Increased libido]]''' - Higher doses of methylphenidate can increase sexual desire, although this enhancement is reported to be less intense and reliable than amphetamines and cocaine.  
*'''[[Effect::Increased libido]]''' - Higher doses of methylphenidate can increase sexual desire.
*'''[[Effect::Pupil dilation]]'''
*'''[[Effect::Pupil dilation]]''' - This effect is experienced only at common to high dosages as well as in low lighting and is more prominent on the comedown.
*'''[[Temporary erectile dysfunction]]'''
}}
}}
|{{effects/cognitive|
|{{effects/cognitive|


*'''[[Effect::Anxiety]]''' - Anxiety is reported with slightly more frequency than other common stimulants like [[amphetamine]] or [[cocaine]].  
*'''[[Effect::Anxiety]]''' - Anxiety is reported with slightly more frequency than other common stimulants like [[amphetamine]] or [[cocaine]].  
*'''[[Effect::Cognitive euphoria]]''' - Compared to other stimulants such as [[amphetamine]], this effect is mild but occasionally occurs at higher or non-orally administered doses .
*'''[[Effect::Cognitive euphoria]]''' - The cognitive effects of methylphenidate are oftentimes subjectively perceived as being more clearheaded and “functional” compared to other strong stimulants such as [[cocaine]].
*'''[[Effect::Ego inflation]]'''
*'''[[Effect::Ego inflation]]'''
*'''[[Effect::Emotion suppression]]''' - This is typically most intense at light and common doses, and is more commonly reported from medical usage rather than recreational.
*'''[[Effect::Emotion suppression]]''' - This is typically most intense at light and common doses, and is more commonly reported from medical usage rather than recreational.
Line 139: Line 141:


===Combination with alcohol===
===Combination with alcohol===
Methylphenidate (when taken orally) has a low bioavailability around 30%. If taken with alcohol (ethanol), blood plasma levels of dexmethylphenidate are increased by up to 40%. However, only a few percent of the consumed methylphenidate is converted to ethylphenidate, so a pharmacologically significant dose with measurable physiological effects would never be produced.<ref>{{cite journal | vauthors=((Patrick, K.)), ((Straughn, A.)), ((Minhinnett, R.)), ((Yeatts, S.)), ((Herrin, A.)), ((DeVane, C.)), ((Malcolm, R.)), ((Janis, G.)), ((Markowitz, J.)) | journal=Clinical pharmacology and therapeutics | title=Influence of Ethanol and Gender on Methylphenidate Pharmacokinetics and Pharmacodynamics | volume=81 | issue=3 | pages=346–353 | date= March 2007 | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188424/ | issn=0009-9236 | doi=10.1038/sj.clpt.6100082}}</ref> A metabolite called [[ethylphenidate]] is also formed.<ref>{{cite journal | vauthors=((Markowitz, J. S.)), ((DeVane, C. L.)), ((Boulton, D. W.)), ((Nahas, Z.)), ((Risch, S. C.)), ((Diamond, F.)), ((Patrick, K. S.)) | journal=Drug Metabolism and Disposition: The Biological Fate of Chemicals | title=Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol | volume=28 | issue=6 | pages=620–624 | date= June 2000 | issn=0090-9556}}</ref>
 
Methylphenidate (when taken orally) has a low bioavailability around 30%. If taken with alcohol (ethanol), blood plasma levels of dexmethylphenidate are increased by up to 40%.<ref>{{cite journal | vauthors=((Patrick, K.)), ((Straughn, A.)), ((Minhinnett, R.)), ((Yeatts, S.)), ((Herrin, A.)), ((DeVane, C.)), ((Malcolm, R.)), ((Janis, G.)), ((Markowitz, J.)) | journal=Clinical pharmacology and therapeutics | title=Influence of Ethanol and Gender on Methylphenidate Pharmacokinetics and Pharmacodynamics | volume=81 | issue=3 | pages=346–353 | date= March 2007 | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188424/ | issn=0009-9236 | doi=10.1038/sj.clpt.6100082}}</ref> A metabolite called [[ethylphenidate]] is also formed.<ref>{{cite journal | vauthors=((Markowitz, J. S.)), ((DeVane, C. L.)), ((Boulton, D. W.)), ((Nahas, Z.)), ((Risch, S. C.)), ((Diamond, F.)), ((Patrick, K. S.)) | journal=Drug Metabolism and Disposition: The Biological Fate of Chemicals | title=Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol | volume=28 | issue=6 | pages=620–624 | date= June 2000 | issn=0090-9556}}</ref>
 
====Alcohol induced dose dumping (AIDD)====
{{headerpanel|{{Template:Warning/Alcohol_induced_dose_dumping_(AIDD)}}}}
 
In vitro data suggest that some extended-release stimulants may experience dose dumping in the presence of alcohol. This is a concern because the ADHD patient population is at risk for alcohol abuse. The potential for dose dumping when taking extended-release stimulants with alcohol could lead to unintended and dangerous side effects for those with ADHD.<ref>{{cite journal |last1=Jain |first1=R |last2=Stark |first2=JG |title=Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications. |journal=Postgraduate medicine |date=September 2016 |volume=128 |issue=7 |pages=672-81 |doi=10.1080/00325481.2016.1218259 |pmid=27467139}}</ref>
 
An example of an extended-release formula includes the methylphenidate medication brand Concerta.


===Dangerous interactions===
===Dangerous interactions===
Line 154: Line 164:
*'''Austria''': Methylphenidate is legal for medical use under the AMG (Arzneimittelgesetz Österreich) and illegal when sold or possessed without a prescription under the SMG (Suchtmittelgesetz Österreich).{{citation needed}}
*'''Austria''': Methylphenidate is legal for medical use under the AMG (Arzneimittelgesetz Österreich) and illegal when sold or possessed without a prescription under the SMG (Suchtmittelgesetz Österreich).{{citation needed}}
*'''Canada''': Methylphenidate is listed in Schedule III of the Controlled Drugs and Substances Act (along with LSD, psychedelic mushrooms, and mescaline).<ref>{{cite web|url=http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-32.html#h-28|title=SCHEDULE III|publisher=Department of Justice|access-date=December 24, 2019|archive-url=https://web.archive.org/web/20110416090043/http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-32.html#h-28|archive-date=April 16, 2011}}</ref> It is illegal to possess without a prescription pursuant to Part G (section G.01.002) of the Food and Drug Regulations under the Food and Drugs Act.
*'''Canada''': Methylphenidate is listed in Schedule III of the Controlled Drugs and Substances Act (along with LSD, psychedelic mushrooms, and mescaline).<ref>{{cite web|url=http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-32.html#h-28|title=SCHEDULE III|publisher=Department of Justice|access-date=December 24, 2019|archive-url=https://web.archive.org/web/20110416090043/http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-32.html#h-28|archive-date=April 16, 2011}}</ref> It is illegal to possess without a prescription pursuant to Part G (section G.01.002) of the Food and Drug Regulations under the Food and Drugs Act.
*'''France''': Methylphenidate is scheduled as a "stupéfiant", i.e. a recognized drug of abuse. It can only be prescribed on a narcotic prescription form.<ref>{{Citation | title=Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants | url=https://www.legifrance.gouv.fr/loda/id/JORFTEXT000000533085/2020-11-20/}}</ref>
*'''Germany''': Methylphenidate is a controlled substance under Anlage III of the BtMG. It can only be prescribed on a narcotic prescription form.<ref>{{Citation | title=Anlage III BtMG - Einzelnorm | url=http://www.gesetze-im-internet.de/btmg_1981/anlage_iii.html}}</ref>
*'''Germany''': Methylphenidate is a controlled substance under Anlage III of the BtMG. It can only be prescribed on a narcotic prescription form.<ref>{{Citation | title=Anlage III BtMG - Einzelnorm | url=http://www.gesetze-im-internet.de/btmg_1981/anlage_iii.html}}</ref>
*'''New Zealand''': Methylphenidate is a 'Class B2 controlled substance'. Unlawful possession is punishable by six-month prison sentence and the distribution of it is punishable by a 14-year sentence.{{citation needed}}
*'''New Zealand''': Methylphenidate is a 'Class B2 controlled substance'. Unlawful possession is punishable by six-month prison sentence and the distribution of it is punishable by a 14-year sentence.{{citation needed}}
*'''Sweden''': Methylphenidate is a List II controlled substance with recognized medical value. Possession without a prescription is punishable by up to three years in prison.<ref>{{Citation | title=Narkotikastrafflag (1968:64) (NSL), Lagen.nu | url=https://lagen.nu/1968:64}}</ref>
*'''Sweden''': Methylphenidate is a List II controlled substance with recognized medical value. Possession without a prescription is punishable by up to three years in prison.<ref>{{Citation | title=Narkotikastrafflag (1968:64) (NSL), Lagen.nu | url=https://lagen.nu/1968:64}}</ref>
*'''Switzerland''': Methylphenidate is a controlled substance specifically named under Verzeichnis A. Medicinal use is permitted.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''Switzerland''': Methylphenidate is a controlled substance specifically named under Verzeichnis A. Medicinal use is permitted.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''Turkey''': Methylphenidate is a 'red prescription' only substance<ref>KIRMIZI REÇETEYE TABİ İLAÇLAR | https://www.titck.gov.tr/storage/Archive/2019/contentFile/K%C4%B1rm%C4%B1z%C4%B1%20Re%C3%A7eteye%20Tabi%20%C4%B0la%C3%A7lar%2005072019_ebcc7e92-6661-4983-870a-fe8983a9c2b7.pdf</ref> and illegal when sold or possessed without a prescription.{{citation needed}}
*'''Turkey''': Methylphenidate is a 'red prescription' only substance<ref>https://www.titck.gov.tr/dinamikmodul/43</ref> and illegal when sold or possessed without a prescription.{{citation needed}}
*'''United Kingdom''': Methylphenidate is a controlled 'Class B' substance. Possession without prescription carries with a sentence up to 5 years and/or an unlimited fine and supplying it is 14 years and/or an unlimited fine.<ref>{{Citation | title=Misuse of Drugs Act 1971 | url=https://www.legislation.gov.uk/ukpga/1971/38/schedule/2}}</ref>
*'''United Kingdom''': Methylphenidate is a controlled 'Class B' substance. Possession without a prescription carries with it a sentence of up to 5 years and/or an unlimited fine and supplying it is 14 years and/or an unlimited fine.<ref>{{Citation | title=Misuse of Drugs Act 1971 | url=https://www.legislation.gov.uk/ukpga/1971/38/schedule/2}}</ref>
*'''United States''': Methylphenidate is classified as a Schedule II controlled substance, the designation used for substances that have a recognized medical value but present a high potential for abuse.{{citation needed}}
*'''United States''': Methylphenidate is classified as a Schedule II controlled substance, the designation used for substances that have a recognized medical value but present a high potential for abuse.{{citation needed}}


Line 175: Line 186:
*[https://www.erowid.org/pharms/methylphenidate/ Methylphenidate (Erowid Vault)]
*[https://www.erowid.org/pharms/methylphenidate/ Methylphenidate (Erowid Vault)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=565 Methylphenidate (Isomer Design)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=565 Methylphenidate (Isomer Design)]
*[https://go.drugbank.com/drugs/DB00422 Methylphenidate (DrugBank)]
*[https://go.drugbank.com/drugs/DB06701 Dexmethylphenidate (DrugBank)]
*[https://drugs-forum.com/wiki/Methylphenidate Methylphenidate (Drugs-Forum)]


==Literature==
==Literature==
Retrieved from "http://psy.st/wiki/Methylphenidate"